TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Clinical trial NCT06232759 · COMPLETED
Trial details
- NCT number
- NCT06232759
- Sponsor
- Guangxi Medical University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2023-10-30
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.